Abstract. Pasteurella multocida is an important pathogen that leads to a range of diseases that have severe economic consequences on cattle production. In order to develop an effective cross-protective component vaccine, an immunoproteomics approach was used to analyze outer membrane proteins (OMPs) of the P. multocida serotype A, B and F strains. Candidate antigen molecules from the whole genome were screened via linear trap quadrupole mass spectrometry and bioinformatics analysis, and the reactogenicity of the candidate antigen molecules was analyzed via cloning, expression, and ELISA or protein immunoblotting, and the vaccine efficacy of the candidate molecules was determined in infective animal models and cross-protective antigens may be obtained. rPmCQ2_2g0128, rPmCQ2_1g0327 and rPmCQ2_1g0020 proteins were selected. Their protective rates were 40/30/20% (rPmCQ2_2g0128), 50/40/0% (rPmCQ2_1g0327) and 0/40/30% (rPmCQ2_1g0020) against ten-fold median lethal dose (10LD 50 ) of the P. multocida serotypes A, B and F in a mouse model, respectively. The results suggested that the two proteins rPmCQ2_2g0128 and rPmCQ2_1g0327 may be used as vaccine candidates against bovine P. multocida serotypes A, B. To the best of our knowledge, the present study was the first to identify cross-protective antigens, extracted OMPs from bovine P. multocida.
Introduction
Pasteurella multocida (P. multocida) is an important opportunistic pathogen that leads to a range of diseases in domestic and wild animals, including cattle (1), pigs (2) , rabbits (3) and birds (4) . P. multocida strains are classified into five serotypes: A, B, D, E and F, based on the capsular composition and 1-16 somatic serovars (5, 6) . The P. multocida serotypes A, B and F are the primary serotypes responsible for bovine pneumonia and hemorrhagic septicemia, and abscesses, otitis and septicemia in rabbits (7) (8) (9) . In addition, the P. multocida serotype A:1 (Pm A:1) is associated with fatal pneumonia and septicemia in cattle and buffaloes (10) , which are responsible for 30% of cattle deaths worldwide and $1 billion in annual loss for beef cattle production in North America (11) .
Vaccinations with inactivated bacteria (bacterins) or live attenuated bacteria is an effective and economic method for improving the condition of and protecting animals against P. multocida infections (11) . However, P. multocida bacterins provide limited protection for heterologous serotype and the live/attenuated vaccines may revert to virulence, thus infecting animals (8) . Therefore, the present study focused on P. multocida immunogens that elicit cross-protective immunity and may be used in vaccines against pasteurellosis (12) . Outer membrane proteins (OMPs) provide protective immunity against P. multocida infection (13) ; therefore, OMPs may be primary protective antigens. Therefore, the P. multocida outer membrane proteome may aid in identifying potential vaccine candidates and diagnostic antigens. A high immunogenicity lipoprotein in P. multocida, PlpE, provided 80-100% protection in mice and induced cross-serotype protective immunity (14) . The recombinant adhesive protein rCp39 provided high levels of protection from fowl cholera in chickens via challenge-exposure with the parental strain P-1059 or the heterologous strain X-73 (serotype A:1) compared with various other vaccines, e.g., PlpB and MOMPs (15) . Iron-regulated OMPs (IROMPs) provided protection against P. multocida in rabbits (16) and calves (17, 18) . The recombinant OmpH-based vaccine provided cross-protection against avian P. multocida strains (15) . These recombinant proteins may be used as subunit vaccines, which are safe and efficient for immuno-compromised animals; however, they provide limited protection against heterologous serotypes. Therefore, identifying cross-protective antigens OMP preparation. OMPs were prepared in accordance with previously described protocols (19) (20) (21) . The bacteria cell cultures were harvested by centrifugation at 10,000 x g for 15 min at 4˚C. The pellets were washed 3 times with cold, sterile PBS (pH 7.4) and resuspended in PBS (pH 7.4) containing 8% Triton X-114, 0.5% 3-(3-cholamidopropyl)-dimethylammo nio]-1-propanesulfonate and 1 mmol/l phenylmethylsulfonyl fluoride, and maintained at 4˚C for 3 h. The cell debris was removed via centrifugation at 10,000 x g and 4˚C for 10 min, and the aqueous phase was collected and 10 µg OMPs were detected by using 12% SDS-PAGE gel. The gelatinous decontamination phase was added into 1:9 volume absolute ethanol, and the pellets were collected by centrifugation at 10,000 x g and 4˚C for 30 min, washed twice with PBS, and dissolved into PBS. Concentration of OMPs was determined using the Bradford method (Bradford Protein Assay kit; Bio-Rad Laboratories, Inc., Hercules, CA, USA). 
Western blot analysis and linear trap quadrupole (LTQ)/mass spectrometry (MS

com).
Protein expression and purification. The target genes were amplified from the genomic DNA of strain PmCQ2. DNApol was from Takara Biotechnology Co., Ltd. (Chongqing, China) and the primers for the selected genes are presented in Table I . The products of polymerase chain reaction (94˚C for 3 min, 94˚C for 1 min, 50˚C for 1 min, 72˚C for 1 min, 35 cycles at 72˚C for 10 min, stored at 4˚C) were cloned into pET-28a plasmid (Takara Biotechnology Co., Ltd.) in E.coli DH5α (Takara Biotechnology Co., Ltd.), expressed in E. coli BL21 (DE3; Takara Biotechnology Co., Ltd.), cultured at 37˚C in LB broth or on agar supplemented with 100 µg/ml kanamycin (Sigma-Aldrich; Merck KGaA) and induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (Sigma-Aldrich; Merck KGaA) at 30˚C or 37˚C for 4 h. The recombinant proteins were purified using affinity chromatography and Ni-NTA Superflow cartridges (Qiagen GmbH, Hilden, Germany).
Anti-serum preparation. A total of 4 P. multocida-antibody-free calves were purchased from a farm in Chongqing.
One calf was immunized intramuscularly in the neck with 4.8x10 10 colony forming unit (CFU)-inactivated PmCQ2, which was fully emulsified with an equal volume of Freund's incomplete adjuvant (Sigma-Aldrich; Merck KGaA) following 3 administrations with 10-day intervals between each. The blood was collected for anti-serum (PmCQ2-VS) separation. A second calf was intramuscularly injected in the neck with 4.8x10 10 CFU live PmCQ2. Following 3 injections with the same dose at 10-day intervals for each dose, the antiserums (PmCQ2-IS) obtained from the calf were separated post-infection at 30 days. The remaining two calves were intranasally infected with 4.8x10 10 CFU live PmB and PmF 3 times. The calves were injected 3 times with the same dose, at 10 day intervals for each dose. Subsequently, the antiserums (PmB-IS and PmF-IS) were separated post-infection at 30 days.
Indirect ELISA. Recombinant protein was dissolved in coating buffer (0.5 M carbonate buffer; pH 9.6) and added to the well (10 µg protein/well) of 96-well microplates (Nunc-Immuno™ MicroWell; Merck KGaA) and then incubated at 4˚C overnight. Plates were washed three times with PBS containing 0.05% Tween 20 (PBST), blocked for prevention of non-specific binding with 200 µl 2% skimmed milk (Sigma-Aldrich; Merck KGaA) at 37˚C for 1 h. A 1:100 dilution of bovine serum in blocking buffer was added to each well and incubated at 37˚C for 1 h. Following washing three times each for 20 min with PBST, a 1:20,000 dilution of horseradish peroxidase-conjugated rabbit anti-bovine IgG antibodies (SAB3700018; Sigma-Aldrich; Merck KGaA) in blocking buffer was added to each well and incubated continuously at 37˚C for 1 h, then washed three times each for 20 min with PBST. Then, 100 µl substrate solution 30 mg o-phenylenediaminedihydrochloride (Takara Biotechnology Co., Ltd.) in 100 ml substrate buffer (0. 
Results
OMP extraction and western blot analysis.
The OMPs were extracted using Triton X-114 from P. multocida serotype A, B and F strains. The OMPs were identified by SDS-PAGE (Fig. 1A ) western blot analysis (Fig. 1B) of PmCQ2-IS serum. A ~57 kDa common OMP band was observed in PmCQ2, PmCQ6, PmB and PmF (indicated by black arrows in Fig. 1) , and a clear 34 kDa OMP band in PmCQ2 and PmCQ6 (indicated by red arrows in Fig. 1) . To identify the candidate cross-protective antigens for P. multocida serotype A, the two gel bands were cut out and used for LTQ/MS analyses. 
LTQ/MS and bioinformatics analysis. Based on the LTQ/MS
analysis, the protein sequences were compared with the Uniprot database (www.uniprot.org) and our bovine P. multocida genome database. A total of 6 protein sequences were matched and are presented in Table II . These protein sequences were predicted as secretory proteins using TMHMM Server.2.0 (22), SignalPv3.0 (23), PSORTb (24) and GPI-SOM (25) . A total of 6 protein sequences contained a signal peptide, and 3 secretory proteins were predicted from the bioinformatics analysis (Table I) . Using the aforementioned combined analyses, 6 protein sequences were cloned and purified.
Recombinant protein selection. The sera for PmCQ2-VS, PmCQ2-IS, PmB-IS and PmF-IS were used to test the reactivities of 6 recombinant proteins using an indirect ELISA (Table III) . rPmCQ2_3g0306, rPmCQ2_2g0128, rPmCQ2_3g0121 and rPmCQ2_2g0046 had the high reactogenicity to PmCQ2-IS; however, only rPmCQ2_1g0327 and rPmCQ2_1g0020 were able to react with the 4 sera. Therefore, the present study used r-PmCQ2_2g0128, r-PmCQ2_1g0327 and r-PmCQ2_1g0020 to verify potential cross-protective antigens and diagnostic antigens for P. multocida serotype A.
Characterization and protective efficacy of recombinant proteins. The present study extracted genomic DNA from the PmCQ2, PmB, PmF and E. coli strains to amplify recombinant proteins (Fig. 2) . PmCQ2_1g0020 and PmCQ2_2g0128 DNA were amplified in PmCQ2, PmB and PmF ( Fig. 2A and C,  respectively) . However, PmCQ2_1g0327 DNA was not amplified in PmB and PmF (Fig. 2B) . The purity of recombinant proteins was determined using SDS-PAGE, which revealed single bands with the molecular masses 34, 35 and 57 kDa (Fig. 2D) . The identity and integrity of the recombinant proteins (rPmCQ2_1g0020, rPmCQ2_1g0327 and rPmCQ2_2g0128) were determined using western blotting (Fig. 2E) . The homology analysis was performed with Clustal X software version 2.0 (http://www.ebi.ac.uk/tools/clustalw2) on PmCQ2_1g0327 and different P. multocida strains that contained PmCQ2, PmCQ6, PmB, PmF, 5 additional bovine P. multocida (isolated from the lungs of diseased cattle in our laboratory), 1 poultry P. multocida (isolated from the lungs of diseased anseriformes in our laboratory) and 27 additional P. multocida genome sequences from the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). Sequence analysis revealed that Pm CQ2_ 1g0327 exhibited a 100% sequence match to Pmu_17770 and PmCQ6_c4301g0004 in P. multocida serotype A Pm36950 and PmCQ6 strains (Fig. 3) .
In order to evaluate the protective efficacy of these proteins, mice were immunized with 100 µg/dose purified r-PmCQ2_2g0128, r-PmCQ2_1g0327 and r-PmCQ2_1g0020. Therefore, it was determined that up to 7 days after a challenge with PmCQ2, r-PmCQ2_1g0327 and r-PmCQ2_2g0128 proteins provided improved survival rates (50 and 40%, respectively) compared with PBS alone (control group) and r-PmCQ2_1g0020 (0%). No statistically significant difference was identified between the protection percentages (30-40%) of these three proteins against PmB. However, the protection percentages against PmF were low or zero (Fig. 4) .
Discussion
Pasteurella is a major respiratory infection in farm and wild animals that has various symptoms, such as swine plague, bovine pneumonia, hemorrhagic septicemia in cattle and abscesses, otitis, and septicemia in rabbit, cholera fowl and swine atrophic rhinitis (1-4). P. multocida is the opportunistic pathogen responsible for this contagious disease. At present, commercially available vaccines are live attenuated vaccines and bacterin vaccines. The bacterins of P. multocida provided limited protection to heterologous serotypes and the live or attenuated vaccines may reverse the virulence of the animal disease. Based on the inevitable disadvantages, it is challenging to develop novel vaccine formulations which are effective, safe, have low production costs, and practicality for herd health (26) . Bacterial OMPs are highly immunogenic and expose epitopes in the P. multocida envelope, which are important for conferring protective immunity in a range of infection models. Previous studies determined that the avian P. multocida PlpB protein was a cross-protective antigen (27) , and this protein was located in the P. multocida outer membrane (28) . The present study extracted OMPs from the different bovine P. multocida strains. Two protein bands were identified (30-40 kDa special bands and 50-60 kDa common bands) by western blot analysis of PmCQ2-infected serum. Based on the LTQ/MS analyses, 6 proteins were cloned, expressed, purified and used for an indirect ELISA. Based on the P/N values, it is possible that r-PmCQ2_3g0306, r-PmCQ2_2g0128, r-PmCQ2_3g0121 and r-PmCQ2_2g0046 represent potential diagnostic antigens for the P. multocida serotype A, based on high P/N values with PmCQ2-IS. The r-PmCQ2_1g0327 and r-PmCQ2_1g0020 antigens may be potential cross-protective antigens due to the high P/N values for the different serotypes A, B and F. Subsequently, 3 proteins were selected for evaluation of their protective efficacy in mice. The findings of the present study revealed that the r-PmCQ2_1g0327 and r-PmCQ2_2g0128 exhibited 40-50% survival rates and may induce cross-immunity in mice against the P. multocida serotype A and B strains. The homology analysis revealed that PmCQ2_1g0327 exhibited 100% sequence identity with three P. multocida serotype A strains; therefore, PmCQ2_1g0327 may be used as a diagnostic antigen for P. multocida serotype A strains. However, the function of this protein requires further investigation. B-cell epitopes have an important role in vaccine development and disease diagnosis (29, 30) . Epitope identification provides valuable information that is essential for understanding antigen components (31) . The present study did not identify PmCQ2_1g0327 in the PmB and PmF genomes; however, r-PmCQ2_1g0327 protected against a PmB infection challenge. Therefore, the present study identified the B-cell epitopes for associated genes in PmCQ2 and PmB using the Protean software and the DNAStar package. The findings revealed specific antigenic epitopes, which were similar to r-PmCQ2_1g0327 in PmCQ2 and PmB.
In conclusion, r-PmCQ2_1g0327 and r-PmCQ2_1g0020 may serve as cross-protective antigens or effective vaccine components against infection with P. multocida serotypes A and B. However, the two recombinant proteins require additional investigation to verify protective immunity in cattle and confirm potential cross-protective antigens to develop P. multocida vaccines. In addition, the protective immunity of the residual proteins (r-PmCQ2_3g0306, r-PmCQ2_3g0121 and r-PmCQ2_2g0046) require investigation, as they exhibit higher OD values with the live PmCQ2 infected serum and not the inactivated PmCQ2 immune serum. Therefore, these proteins may be serve as diagnostic antigens for P. multocida serotype A strains. Additionally, the ELISA assay platform with specific sera (three serotypes) was a useful tool for the selection of protective and diagnostic antigens.
A previous study suggested that identifying OMPs may be important in the development of novel vaccine candidates and diagnostic antigens (32) . Therefore, future studies should focus on the development of novel vaccines for P. multocida strains, and the generation of fusion proteins that may provide improved protection against different P. multocida strains. 
